Mitotic rate and subcutaneous involvement are prognostic factors for survival after recurrence in patients with only locoregional skin metastasis as the first site of recurrence from cutaneous melanoma

Messeguer, F.; Agustí-Mejias, Anna; Traves, Víctor; Requena, Celia; Alegre, V.; Guillén, C.; Oliver, V.; Nagore, Eduardo

doi:10.1111/j.1468-3083.2012.04454.x

Cited by 9 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Valencia, prospective melanoma cases, seen between January 2004 and July 2013, were all included in the melanoma database of the dermatology department of the Instituto Valenciano de Oncologia ( N = 463). The characteristics of this database have been described in detail elsewhere . For Barcelona, melanoma cases submitted to SLN biopsy were collected from the Melanoma Unit at the Hospital Clinic of Barcelona between October 1996 and 2013 and were recruited from Catalonia as well as further a field as the melanoma clinic at the Hospital Clinic Barcelona is a secondary and tertiary referral center ( N = 678).…”

Section: Methodsmentioning

confidence: 99%

High nevus counts confer a favorable prognosis in melanoma patients

Ribero

Davies

Requena

et al. 2015

Intl Journal of Cancer

View full text Add to dashboard Cite

A high number of naevi is the most significant phenotypic risk factor for melanoma and is in part genetically determined. The number of naevi decreases from middle age onwards but this senescence can be delayed in melanoma patients. We investigated the effects of naevus number count on sentinel node status and melanoma survival in a large cohort of melanoma cases. Out of 2184 melanoma cases, 684 (31.3%) had a high naevus count (>50). High naevus counts were associated with favourable prognostic factors such as lower Breslow thickness, less ulceration and lower mitotic rate, despite adjustment for age. Naevus count was not predictive of sentinel node status. The crude 5- and 10-year melanoma specific survival rate was higher in melanomas cases with a high naevus count compared to those with a low naevus count (91.2% vs 86.4% and 87.2% vs 79%, respectively). The difference in survival remained significant after adjusting for all known melanoma prognostic factors (HR= 0.43, CI 0.21-0.89). The favourable prognostic value of a high naevus count was also seen within the positive sentinel node subgroup of patients (HR=0.22, CI 0.08-0.60). High naevus count is associated with a better melanoma survival, even in the subgroup of patients with positive sentinel lymph node. This suggests a different biological behaviour of melanoma tumours in patients with an excess of naevi.

show abstract

Section: Methodsmentioning

confidence: 99%

High nevus counts confer a favorable prognosis in melanoma patients

Ribero

Davies

Requena

et al. 2015

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Increasing thickness means ascending rate of recurrence and metastasis. [3][4][5] Special AT-rich sequence binding protein 1 (SATB1) is a nuclear matrix attachment DNA-binding protein, which is predominantly expressed in thymocytes and central nervous system. 6,7 SATB1, generally acknowledged as a genome organizer, tethers multiple genomic loci and recruits chromatin-remodeling enzymes to regulate the chromatin structure and gene expression.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of SATB1 by shRNA Suppresses the Proliferation of Cutaneous Malignant Melanoma

Zhang

Fang

et al. 2014

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Overexpression of special AT-rich sequence binding protein 1 (SATB1), a global genome organizer, as a predictor of poor prognosis in cutaneous malignant melanoma (CMM) attracted great interest in previous research. In this article, upregulated SATB1 was observed in three melanoma cell lines and in eight CMM tissues. After downregulating SATB1 by RNAi, proliferation of A375 was suppressed in vitro and in vivo. In summary, the proliferation of CMM could be related closely to the SATB1 gene. Interference of this gene may be a promising method for CMM therapy.

show abstract

“…From the Sydney Melanoma Unit, Francken and colleagues commented that the 5‐year survival for in‐transit recurrences (> 3 cm from the original tumour) was 44% ( n = 86) and for distant subcutaneous recurrences the 5‐year survival was only 9% ( n = 27). Messeguer and colleagues recently reported on a subset of 36 patients with locoregional skin metastasis with an estimated 5‐year survival of 52% and found that the mitotic rate of the primary tumour and the subcutaneous involvement of the metastasis influenced survival; factors which were not examined in our series.…”

Section: Discussionmentioning

confidence: 81%

“…Where surgery had not been undertaken at the VMS, a histopathological review to confirm the diagnosis of cutaneous metastases was obtained from VMS pathologists. We grouped what has been called local, satellite, intralymphatic or in‐transit metastases to avoid the varying and arbitrary distinctions between these different entities and to maintain uniformity. It is often difficult to accurately categorise metastases in the region clinically and we therefore chose to group them.…”

Section: Methodsmentioning

confidence: 99%